Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from MIRA Pharmaceuticals, Inc. ( (MIRA) ) is now available.
MIRA Pharmaceuticals announced the FDA clearance of its IND application for Ketamir-2, allowing the initiation of U.S.-based clinical trials for this non-opioid drug candidate aimed at treating neuropathic pain. The company is advancing through Phase 1 trials and plans to start Phase 2a trials by the end of 2025. Additionally, MIRA is progressing with the acquisition of SKNY Pharmaceuticals and the development of MIRA-55, which has shown promising results in preclinical studies.
The most recent analyst rating on (MIRA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on MIRA Pharmaceuticals, Inc. stock, see the MIRA Stock Forecast page.
More about MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on developing novel oral drug candidates. The company targets neuropathic pain and other conditions with products like Ketamir-2, an NMDA receptor antagonist, and has ongoing programs in obesity, nicotine craving, and inflammatory pain.
Average Trading Volume: 1,478,912
Technical Sentiment Signal: Strong Buy
For an in-depth examination of MIRA stock, go to TipRanks’ Overview page.